Details
Stereochemistry | ACHIRAL |
Molecular Formula | 2C19H32N2.3C4H4O4 |
Molecular Weight | 925.158 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 3 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
OC(=O)\C=C\C(O)=O.OC(=O)\C=C\C(O)=O.OC(=O)\C=C\C(O)=O.C(C1CC1)N2CC3CN(CC4CC4)CC(C2)C35CCCC5.C(C6CC6)N7CC8CN(CC9CC9)CC(C7)C8%10CCCC%10
InChI
InChIKey=AZPYPAVFNGFTGB-VQYXCCSOSA-N
InChI=1S/2C19H32N2.3C4H4O4/c2*1-2-8-19(7-1)17-11-20(9-15-3-4-15)12-18(19)14-21(13-17)10-16-5-6-16;3*5-3(6)1-2-4(7)8/h2*15-18H,1-14H2;3*1-2H,(H,5,6)(H,7,8)/b;;3*2-1+
Molecular Formula | C4H4O4 |
Molecular Weight | 116.0722 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 1 |
Optical Activity | NONE |
Molecular Formula | C19H32N2 |
Molecular Weight | 288.4708 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
Tedisamil is an antiarrhythmic with additional anti-ischaemic properties, which acts via potassium channel blockade. This drug can be categorised as a class III antiarrhythmic agent due to its effects of action potential and QT interval prolongation in these patients. Although tedisamil has been shown to be an effective anti-ischaemic agent, with Phase III trials for angina pectoris now completed, the company are now pursuing the use of tedisamil for the treatment of atrial fibrillation, for which tedisamil is still in Phase II/III clinical trials. The FDA’s Cardiovascular and Renal Drugs Advisory Committee voted not to recommend approval for Solvay Pharmaceuticals’ investigational anti-arrhythmic drug Pulzium (Tedisamil) and asked the company to give the FDA more information.
Originator
Approval Year
PubMed
Title | Date | PubMed |
---|---|---|
Tedisamil and dofetilide-induced torsades de pointes, rate and potassium dependence. | 2001 Apr |
|
Transgenic mice overexpressing human KvLQT1 dominant-negative isoform. Part II: Pharmacological profile. | 2001 May |
|
Tedisamil and lidocaine enhance each other's antiarrhythmic activity against ischaemia-induced arrhythmias in rats. | 2003 Aug |
|
Modulation of intracellular Ca(2+) concentration by tedisamil, a class III antiarrhythmic agent, in isolated heart preparation. | 2003 Aug 22 |
|
Tedisamil in coronary disease: additional benefits in the therapy of atrial fibrillation? | 2003 Jun |
|
Trials of new antiarrhythmic drugs for maintenance of sinus rhythm in patients with atrial fibrillation. | 2004 |
|
Effect of the antifibrillatory compound tedisamil (KC-8857) on transmembrane currents in mammalian ventricular myocytes. | 2004 Dec |
|
Tedisamil: a new novel antiarrhythmic. | 2004 Feb |
|
Theoretical possibilities for the development of novel antiarrhythmic drugs. | 2004 Jan |
|
Safety and efficacy of intravenously administered tedisamil for rapid conversion of recent-onset atrial fibrillation or atrial flutter. | 2004 Jul 7 |
|
Tedisamil attenuates foetal transformation of myosin in the hypertrophied rat myocardium. | 2004 Nov |
|
Electrical storms in Brugada syndrome: review of pharmacologic and ablative therapeutic options. | 2005 Jan 1 |
|
Do we need pharmacological therapy for atrial fibrillation in the ablation era? | 2006 Dec |
|
Approach to the asymptomatic patients with Brugada syndrome. | 2007 Apr 1 |
|
New antiarrhythmic treatment of atrial fibrillation. | 2007 Jul |
|
Update on atrial fibrillation: part II. | 2008 Mar |
|
New horizons in antiarrhythmic therapy: will novel agents overcome current deficits? | 2008 Sep 22 |
|
Recent advances in pharmacotherapy of atrial fibrillation. | 2009 Aug |
|
The transmembrane beta-subunits KCNE1, KCNE2, and DPP6 modify pharmacological effects of the antiarrhythmic agent tedisamil on the transient outward current Ito. | 2009 Jun |
Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 15 16:04:28 UTC 2023
by
admin
on
Fri Dec 15 16:04:28 UTC 2023
|
Record UNII |
Y4HRG433UU
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C93038
Created by
admin on Fri Dec 15 16:04:28 UTC 2023 , Edited by admin on Fri Dec 15 16:04:28 UTC 2023
|
||
|
NCI_THESAURUS |
C47793
Created by
admin on Fri Dec 15 16:04:28 UTC 2023 , Edited by admin on Fri Dec 15 16:04:28 UTC 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
CHEMBL113461
Created by
admin on Fri Dec 15 16:04:28 UTC 2023 , Edited by admin on Fri Dec 15 16:04:28 UTC 2023
|
PRIMARY | |||
|
150501-62-5
Created by
admin on Fri Dec 15 16:04:28 UTC 2023 , Edited by admin on Fri Dec 15 16:04:28 UTC 2023
|
PRIMARY | |||
|
RR-134
Created by
admin on Fri Dec 15 16:04:28 UTC 2023 , Edited by admin on Fri Dec 15 16:04:28 UTC 2023
|
PRIMARY | |||
|
C73802
Created by
admin on Fri Dec 15 16:04:28 UTC 2023 , Edited by admin on Fri Dec 15 16:04:28 UTC 2023
|
PRIMARY | |||
|
11498917
Created by
admin on Fri Dec 15 16:04:28 UTC 2023 , Edited by admin on Fri Dec 15 16:04:28 UTC 2023
|
PRIMARY | |||
|
100000088488
Created by
admin on Fri Dec 15 16:04:28 UTC 2023 , Edited by admin on Fri Dec 15 16:04:28 UTC 2023
|
PRIMARY | |||
|
SUB22754
Created by
admin on Fri Dec 15 16:04:28 UTC 2023 , Edited by admin on Fri Dec 15 16:04:28 UTC 2023
|
PRIMARY | |||
|
134747
Created by
admin on Fri Dec 15 16:04:28 UTC 2023 , Edited by admin on Fri Dec 15 16:04:28 UTC 2023
|
PRIMARY | |||
|
m10516
Created by
admin on Fri Dec 15 16:04:28 UTC 2023 , Edited by admin on Fri Dec 15 16:04:28 UTC 2023
|
PRIMARY | Merck Index | ||
|
Y4HRG433UU
Created by
admin on Fri Dec 15 16:04:28 UTC 2023 , Edited by admin on Fri Dec 15 16:04:28 UTC 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
PARENT -> SALT/SOLVATE | |||
|
PARENT -> SALT/SOLVATE |
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |